Chemical traits of cerebral amyloid angiopathy in familial British-, Danish-, and non-Alzheimer's dementias.
Humans
Adaptor Proteins, Signal Transducing
/ metabolism
Alzheimer Disease
/ genetics
Amyloid
/ metabolism
Amyloid beta-Peptides
/ metabolism
Amyloid Neuropathies, Familial
Cerebral Amyloid Angiopathy
/ genetics
Dementia
/ pathology
Denmark
Membrane Glycoproteins
/ metabolism
Plaque, Amyloid
England
ABri
ADan
Alzheimer's disease (AD)
cerebral amyloid angiopathy (CAA)
familial British dementia (FBD)
familial Danish dementia (FDD)
Journal
Journal of neurochemistry
ISSN: 1471-4159
Titre abrégé: J Neurochem
Pays: England
ID NLM: 2985190R
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
revised:
11
08
2022
received:
08
06
2022
accepted:
08
09
2022
pubmed:
15
9
2022
medline:
1
11
2022
entrez:
14
9
2022
Statut:
ppublish
Résumé
Familial British dementia (FBD) and familial Danish dementia (FDD) are autosomal dominant forms of dementia caused by mutations in the integral membrane protein 2B (ITM2B, also known as BRI2) gene. Secretase processing of mutant BRI2 leads to secretion and deposition of BRI2-derived amyloidogenic peptides, ABri and ADan that resemble APP/β-amyloid (Aβ) pathology, which is characteristic of Alzheimer's disease (AD). Amyloid pathology in FBD/FDD manifests itself predominantly in the microvasculature by ABri/ADan containing cerebral amyloid angiopathy (CAA). While ABri and ADan peptide sequences differ only in a few C-terminal amino acids, CAA in FDD is characterized by co-aggregation of ADan with Aβ, while in contrast no Aβ deposition is observed in FBD. The fact that FDD patients display an earlier and more severe disease onset than FBD suggests a potential role of ADan and Aβ co-aggregation that promotes a more rapid disease progression in FDD compared to FBD. It is therefore critical to delineate the chemical signatures of amyloid aggregation in these two vascular dementias. This in turn will increase the knowledge on the pathophysiology of these diseases and the pathogenic role of heterogenous amyloid peptide interactions and deposition, respectively. Herein, we used matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI) in combination with hyperspectral, confocal microscopy based on luminescent conjugated oligothiophene probes (LCO) to delineate the structural traits and associated amyloid peptide patterns of single CAA in postmortem brain tissue of patients with FBD, FDD as well as sporadic CAA without AD (CAA+) that show pronounced CAA without parenchymal plaques. The results show that CAA in both FBD and FDD consist of N-terminally truncated- and pyroglutamate-modified amyloid peptide species (ADan and ABri), but that ADan peptides in FDD are also extensively C-terminally truncated as compared to ABri in FBD, which contributes to hydrophobicity of ADan species. Further, CAA in FDD showed co-deposition with Aβ x-42 and Aβ x-40 species. CAA+ vessels were structurally more mature than FDD/FBD CAA and contained significant amounts of pyroglutamated Aβ. When compared with FDD, Aβ in CAA+ showed more C-terminal and less N-terminally truncations. In FDD, ADan showed spatial co-localization with Aβ3pE-40 and Aβ3-40 but not with Aβx-42 species. This suggests an increased aggregation propensity of Aβ in FDD that promotes co-aggregation of both Aβ and ADan. Further, CAA maturity appears to be mainly governed by Aβ content based on the significantly higher 500/580 patterns observed in CAA+ than in FDD and FBD, respectively. Together this is the first study of its kind on comprehensive delineation of Bri2 and APP-derived amyloid peptides in single vascular plaques in both FDD/FBD and sporadic CAA that provides new insight in non-AD-related vascular amyloid pathology. Cover Image for this issue: https://doi.org/10.1111/jnc.15424.
Identifiants
pubmed: 36102248
doi: 10.1111/jnc.15694
pmc: PMC9828067
doi:
Substances chimiques
Adaptor Proteins, Signal Transducing
0
Amyloid
0
Amyloid beta-Peptides
0
Membrane Glycoproteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
233-246Subventions
Organisme : NIA NIH HHS
ID : R01 AG078796
Pays : United States
Organisme : NIA NIH HHS
ID : R21 AG078538
Pays : United States
Informations de copyright
© 2022 The Authors. Journal of Neurochemistry published by John Wiley & Sons Ltd on behalf of International Society for Neurochemistry.
Références
Acta Neuropathol. 2009 Jul;118(1):115-30
pubmed: 19225789
Am J Pathol. 2001 Feb;158(2):515-26
pubmed: 11159188
Am J Pathol. 1998 Sep;153(3):725-33
pubmed: 9736023
ACS Chem Biol. 2013;8(6):1128-33
pubmed: 23521783
Nat Methods. 2007 Dec;4(12):1023-30
pubmed: 18026110
Neurobiol Aging. 2013 May;34(5):1416-25
pubmed: 23261769
Ann N Y Acad Sci. 2000;920:84-92
pubmed: 11193180
J Biol Chem. 2001 Nov 23;276(47):43909-14
pubmed: 11557758
Proc Natl Acad Sci U S A. 2017 Dec 5;114(49):13018-13023
pubmed: 29158413
Proc Natl Acad Sci U S A. 2000 Apr 25;97(9):4920-5
pubmed: 10781099
Neuropathol Appl Neurobiol. 2013 Aug;39(5):498-509
pubmed: 23163235
Acta Neuropathol. 2012 Jan;123(1):1-11
pubmed: 22101365
Neuropathol Appl Neurobiol. 2008 Oct;34(5):492-505
pubmed: 18282158
Lancet Neurol. 2022 Aug;21(8):714-725
pubmed: 35841910
J Biol Chem. 1995 Mar 31;270(13):7013-6
pubmed: 7706234
J Neurochem. 2020 Mar;152(5):602-616
pubmed: 31605538
Acta Neuropathol. 1991;82(4):239-59
pubmed: 1759558
J Biol Chem. 2005 Nov 4;280(44):36883-94
pubmed: 16091362
J Neurochem. 2022 Nov;163(3):233-246
pubmed: 36102248
Cell Mol Life Sci. 2005 Aug;62(16):1814-25
pubmed: 15968464
Anal Chem. 2018 Jul 3;90(13):8130-8138
pubmed: 29856605
Cell Mol Life Sci. 2010 Feb;67(4):581-600
pubmed: 19898742
J Neurol Neurosurg Psychiatry. 2017 Nov;88(11):982-994
pubmed: 28844070
Brain. 2000 May;123 ( Pt 5):975-91
pubmed: 10775542
Brain Pathol. 2006 Jan;16(1):71-9
pubmed: 16612984
Arch Biochem Biophys. 1993 Feb 15;301(1):41-52
pubmed: 8442665
J Intern Med. 2018 Mar;283(3):218-237
pubmed: 29360284
J Neuropathol Exp Neurol. 2002 Mar;61(3):254-67
pubmed: 11895040
J Biol Chem. 2019 Apr 26;294(17):6719-6732
pubmed: 30814252
Chemphyschem. 2016 Aug 18;17(16):2558-66
pubmed: 27146076
Neurosci Lett. 2019 May 14;701:125-131
pubmed: 30807796
Brain. 2016 Nov 1;139(11):2957-2969
pubmed: 27591113
Neuron. 2015 May 6;86(3):632-45
pubmed: 25950632
Nat Rev Neurol. 2020 Jan;16(1):30-42
pubmed: 31827267
Sci Adv. 2021 Jun 16;7(25):
pubmed: 34134980
J Neuropathol Exp Neurol. 1998 Oct;57(10):885-94
pubmed: 9786239
Biochem Biophys Res Commun. 2010 Mar 12;393(3):356-61
pubmed: 20036644
J Phys Chem B. 2018 Dec 13;122(49):11535-11545
pubmed: 30335383
J Neurochem. 2016 Nov;139(4):651-658
pubmed: 27579672
Neurology. 2002 Jun 25;58(12):1791-800
pubmed: 12084879